Calcium Citrate

Evidence Level: L5

Predicted Indications: 4

Calcium Citrate

Pharmacist Assessment Report

Calcium Citrate: From a Calcium Supplement to Hemoglobinopathy

One-Sentence Summary

Calcium citrate is a calcium supplement and citrate source, marketed in India as oral tablets. No approved indication text is available in the data compiled for this report. The TxGNN model predicts it may be effective for hemoglobinopathy with a very high score, but there are 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone.

Quick Overview

Item	Content
Original Indication	Not stated in the available licence data
Predicted New Indication	Hemoglobinopathy
TxGNN Prediction Score	0.9937
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (8 of 8) – CDSCO approval status is not included in this data
Number of Listed Products	8 (valid: 8)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Calcium citrate is a calcium supplement and citrate source. Calcium plays a central role in bone metabolism, and calcium and vitamin D deficiency or inadequate intake is common.

The data compiled for this report found no clear mechanistic link between calcium citrate and hemoglobinopathy. Calcium and bone health matter in thalassemia-related osteoporosis, but that is supportive care, not a disease-modifying effect on the underlying blood disorder. The high TxGNN score (0.9937) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Other top-ranked predictions show the same pattern: several are other hematologic conditions (beta-thalassemia, a rare glycolytic enzyme deficiency, a chromosome 16p deletion) that likely cluster together in the network, and none has trial or literature support. The most evidence-rich prediction is myocardial infarction (4 publications, none a clinical trial of calcium citrate for MI). Its evidence is mixed: a preclinical rat study of citrate pretreatment in ischemia/reperfusion injury, alongside debate over whether calcium supplements raise cardiovascular risk.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for hemoglobinopathy.

For reference, the literature found for the second-ranked prediction (myocardial infarction) is indirect and does not support the hemoglobinopathy prediction:

PMID	Year	Type	Journal	Key Findings
25147494	2014	Review	Food & Nutrition Research	Calcium and vitamin D are essential for bone metabolism; deficiency or inadequate intake is common
27813585	2016	Preclinical (rat model)	Genetics and Molecular Research	Citrate pretreatment studied for effects on ventricular arrhythmia and caspase-3 expression in ischemia/reperfusion injury
24619106	2014	Physiological study	European Journal of Clinical Nutrition	Acute oral calcium load effects on arterial properties and endothelial function in healthy subjects; addresses vascular safety, not MI outcomes
33668039	2021	Bioinformatics	Aging	LncRNA-mRNA co-expression analysis for MI biomarkers; not specific to calcium citrate

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
59815	Dotshine Plus Tablet	Strip of 10 tablets	Not stated
247567	Zadilex Tablet	Strip of 10 tablets	Not stated
37757	Calcilead-HD Tablet	Strip of 10 tablets	Not stated
217118	Tenz-Cal Tablet	Strip of 10 tablets	Not stated
137164	Muscobon Tablet	Strip of 10 tablets	Not stated

All 8 registrations are valid licences for oral tablets; the five above are shown.

Review correction (2026-11-06): Originally stated: “All 8 registrations are valid single-ingredient licences for oral tablets; the five above are shown.” Removed: it described the products as single-ingredient or combination products in a way that did not match the Indian medicine data (the Indian Medicine Dataset as of 2026-11-06). Source: Indian Medicine Dataset.

Safety Considerations

Drug Interactions: 84 interactions were identified in total. The data compiled for this report lists a sample of 20, including:
- Major: Dolutegravir, Bictegravir
- Moderate: Doxycycline, Tetracycline, bisphosphonates (Alendronic acid, Risedronic acid, Ibandronate), calcium channel blockers (Nifedipine, Amlodipine, Diltiazem), beta-blockers (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carvedilol), thiazide diuretics (Hydrochlorothiazide, Chlorothiazide), Baloxavir marboxil, and topical vitamin D analogues (Calcipotriol, Calcitriol)
Cardiovascular consideration: Calcium supplements have been debated for a possible cardiovascular risk. Calcium also acts as a coagulation cofactor, so a theoretical pro-thrombotic concern exists rather than a therapeutic benefit.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a model score, with no clinical trials or literature and no plausible disease-modifying mechanism for hemoglobinopathy. Calcium citrate’s role in thalassemia is limited to supportive bone care, which is not a repurposing indication.

To proceed, the following is needed:

Package insert warnings and contraindications from the India regulator’s materials, to enable safety screening
Mechanism of action data (for example, from DrugBank)
Any clinical or mechanistic evidence linking calcium citrate to hemoglobinopathy beyond supportive bone care
Approved indication text for the registered products

Review Log

Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.

Review date	Item	Action	Source
2026-11-06	Removed: “single-ingredient”	Corrected	Indian Medicine Dataset

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.